tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2013-1-28-34tumors-19Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSМЕЛКОКЛЕТОЧНЫЙ РАК ЛЕГКОГО: СОСТОЯНИЕ ПРОБЛЕМЫ К 2013 ГОДУ И ИЗМЕНЕНИЯ ЗА ПОСЛЕДНИЕ 40 ЛЕТSmall cell lung cancer: status of the problem in 2013 and changes in the last 40 years.БычковМ. Б.BychkovM. B.mbychkov77@yandex.ruФГБУ «РОНЦ им. Н.Н. Блохина» РАМНRussian Federation201320052015012834Copyright © Бычков М.Б., 20152015Бычков М.Б.Bychkov M.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/19

The article describes the small-cell lung cancer, history of development of methods of diagnosis and treatment. Data on modern algorithms of treatment of advanced and localized stages of the disease, the role of prophylactic brain irradiation, highlights issues of targeted therapy and surgical treatment.

мелкоклеточный рак легкогохимиотерапияхимиолучевая терапияметастазы в мозгхирургическое лечениеsmall cell lung cancerchemotherapychemoradiotherapybrain metastasessurgical treatmentReferencesTravis W. D. et al. Patology and genetics of tumors of the lung, pleura, thymus and heart. World Health Organization of Tumors. Vol 10, IARC Press, Lyon, France, 2004.Travis W. D. et al. Patology and genetics of tumors of the lung, pleura, thymus and heart. World Health Organization of Tumors. Vol 10, IARC Press, Lyon, France, 2004.Onoda S., Masuda N., Seto T. et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Croup Study 0301 J. Clin. Oncol, 2006; 24:5448-5453.Onoda S., Masuda N., Seto T. et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Croup Study 0301 J. Clin. Oncol, 2006; 24:5448-5453.Sundstrom S. et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in smaH-cell lung cancer: results from a randomized phase III trial with 5 years follow-up. J. Clin. Oncol, 2002; 20:4665-4672.Sundstrom S. et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in smaH-cell lung cancer: results from a randomized phase III trial with 5 years follow-up. J. Clin. Oncol, 2002; 20:4665-4672.Movsas B. et al. Radiotherapy patterns of care study in lung carcinoma. J. Clin. Oncol, 2003; 21, 4553-59.Movsas B. et al. Radiotherapy patterns of care study in lung carcinoma. J. Clin. Oncol, 2003; 21, 4553-59.By Elsevier, Small Cell lung Cancer: New Therapies Needed for SCLC, 2012, Elsevier Inc., 1-3.By Elsevier, Small Cell lung Cancer: New Therapies Needed for SCLC, 2012, Elsevier Inc., 1-3.Patel S. Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer, 2009; 1 5:842-850.Patel S. Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer, 2009; 1 5:842-850.Slotman В., Faivre-Finn C., Kramer G. et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N. Engl. J., 2007; 357:664-672.Slotman В., Faivre-Finn C., Kramer G. et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N. Engl. J., 2007; 357:664-672.Krug L. M., Pietanza M. C. Emerging therapies in SCLC. ASCO educational book, 2009, 455-460.Krug L. M., Pietanza M. C. Emerging therapies in SCLC. ASCO educational book, 2009, 455-460.Переводчикова Н. И., Бычков М. Б. Мелкоклеточный рак легкого. — М.: Медицина, 1984.Переводчикова Н. И., Бычков М. Б. Мелкоклеточный рак легкого. — М.: Медицина, 1984.Chandra V. et al. The role of pulmonary resection in SCLC. Mayo Clin. Proc., 2006; 81, 5, 619-24.Chandra V. et al. The role of pulmonary resection in SCLC. Mayo Clin. Proc., 2006; 81, 5, 619-24.Lim E. et al. The role of surgery in the treatment of limited disease SCLC: time to reevaluate. J. T. O. 2008, 3, 11, 1267-71.Lim E. et al. The role of surgery in the treatment of limited disease SCLC: time to reevaluate. J. T. O. 2008, 3, 11, 1267-71.Моисеев П. И., Жарков В. В. Роль хирургии в комбинированном лечении больных МРЛ: собственный опыт (1991-2000). Материалы XI Российской онкологической конференции. — Москва, 2007.Моисеев П. И., Жарков В. В. Роль хирургии в комбинированном лечении больных МРЛ: собственный опыт (1991-2000). Материалы XI Российской онкологической конференции. — Москва, 2007.Hanagiri T. et al. Results of surgical treatment of SCLC. J. T. O., 2009, 4, 8, 964.Hanagiri T. et al. Results of surgical treatment of SCLC. J. T. O., 2009, 4, 8, 964.Takashi I. et al. Role of surgery in SCLC. Retrospective analysis of 1991-2007. XIII WCLC, San Francisco, 2009.Takashi I. et al. Role of surgery in SCLC. Retrospective analysis of 1991-2007. XIII WCLC, San Francisco, 2009.Трахтенберг А. Х., Иванов В. П. Хирургическое лечение при мелкоклеточном раке легкого // Рак легкого / Под ред. А. Х. Трахтенберга. — М., 1992, 94-100.Трахтенберг А. Х., Иванов В. П. Хирургическое лечение при мелкоклеточном раке легкого // Рак легкого / Под ред. А. Х. Трахтенберга. — М., 1992, 94-100.Valleres E. Up to Date, 2009.Valleres E. Up to Date, 2009.

The authors declare that there are no conflicts of interest present.